Alto Neuroscience (NYSE:ANRO) Stock Rating Reaffirmed by William Blair

Alto Neuroscience (NYSE:ANRO)‘s stock had its “outperform” rating reaffirmed by equities research analysts at William Blair in a research report issued on Wednesday, RTT News reports.

Other research analysts have also recently issued reports about the company. TD Cowen started coverage on Alto Neuroscience in a research note on Tuesday, February 27th. They set an “outperform” rating on the stock. Jefferies Financial Group began coverage on Alto Neuroscience in a research note on Tuesday, February 27th. They set a “buy” rating and a $33.00 target price on the stock. Robert W. Baird assumed coverage on Alto Neuroscience in a report on Tuesday, February 27th. They set an “outperform” rating and a $32.00 target price for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $32.00 price target on shares of Alto Neuroscience in a research note on Monday, March 25th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $32.33.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $12.82 on Wednesday. The business’s 50 day moving average price is $14.56. Alto Neuroscience has a 1 year low of $12.40 and a 1 year high of $24.00.

Insider Buying and Selling

In related news, CFO Nicholas Conrad Smith acquired 6,150 shares of the firm’s stock in a transaction dated Thursday, March 28th. The stock was acquired at an average price of $16.36 per share, for a total transaction of $100,614.00. Following the purchase, the chief financial officer now owns 26,866 shares of the company’s stock, valued at approximately $439,527.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Institutional Investors Weigh In On Alto Neuroscience

Several institutional investors have recently modified their holdings of ANRO. Price T Rowe Associates Inc. MD purchased a new position in Alto Neuroscience in the first quarter valued at $9,788,000. Vanguard Group Inc. purchased a new position in shares of Alto Neuroscience in the 1st quarter valued at about $8,233,000. Jennison Associates LLC acquired a new stake in shares of Alto Neuroscience during the 1st quarter worth about $7,039,000. AWM Investment Company Inc. purchased a new stake in Alto Neuroscience during the first quarter worth approximately $4,592,000. Finally, University of Texas Texas AM Investment Managment Co. acquired a new position in Alto Neuroscience in the first quarter valued at approximately $340,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.